An open label clinical trial of complement inhibition in multifocal motor neuropathy.
about
Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathyImmunosuppressant and immunomodulatory treatments for multifocal motor neuropathyMMN: from immunological cross-talk to conduction blockThe pathogenesis of multifocal motor neuropathy and an update on current management options.Applying complement therapeutics to rare diseases.Immunotherapy in Peripheral NeuropathiesThe relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activationTerminal complement activation is increased and associated with disease severity in CIDPAntibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.An update in guillain-barré syndromeAdvances in the diagnosis, pathogenesis and treatment of CIDP.Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.Immune pathogenesis and treatment of multifocal motor neuropathy.Recent developments and future directions in Guillain-Barré syndrome.Multifocal motor neuropathy: current therapies and novel strategies.Guillain-Barré syndrome: a century of progress.Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases.Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.Outcome measures in MMN revisited: further improvement needed.Long-term Effects of Intravenous Cyclophosphamide in Combination with Mesna Provided Intravenously and via Bladder Perfusion in a Patient with Severe Multifocal Motor Neuropathy.Complement activity is associated with disease severity in multifocal motor neuropathy.Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study.Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.Guillain-Barré syndrome.
P2860
Q24187418-B394C72E-7A8A-43DF-B5EB-A6F08792EE79Q24200228-4C10A51E-2B34-4CD0-856D-24CABFE9A9ECQ33729418-57F5D2C7-8F67-4E72-8603-85D027BE6528Q35537340-EB22393C-D716-468A-9632-96F1B608EB3CQ36315497-6F7ACD9E-15FF-4253-9EE9-2BE25B274C70Q36484418-AEAB245F-9EF4-4ABC-BA17-4B37B2D40064Q36643354-8615B80A-A36F-48FC-9853-C58006CCA724Q37247076-6C6CCAC9-A69F-4632-BD2A-20E799D135F8Q37494674-98EDC93E-A77C-449F-87DD-DBF5D61D479FQ37544140-F81E1455-B380-46D0-82DC-840F8957F9DCQ37918316-9169F212-0E00-4981-9E05-D833B52D7BF0Q37959252-E3CE0843-3BED-4B15-97F1-F8C66169BB6CQ38006761-C8398BDC-EBC9-4E85-BAF5-BD74A45981B6Q38039965-9D6BD216-7141-4E20-AACC-D1E6E82FC153Q38070887-6F63E24B-2A74-4152-81C8-EC8967C8AA78Q38091664-182818FC-01D7-4EEB-8C14-3B9FF9F85B69Q39011456-8085B095-48C4-43C8-BF28-FF81AF988E83Q39090725-0FEB0A2A-E204-4D6B-A71C-F28F8ADAF416Q39227455-62DAF3C0-68B9-4244-8D68-1F1029753207Q39434973-5E5CB89B-7561-4A5B-8FC2-2FB579E66B3FQ40793045-BDDA447A-2AA0-49D9-B3FF-5BD76332A3DFQ41308052-2996CBC0-4D6D-4258-A060-A95BE120E9D9Q41613835-579FECB0-F654-4DA7-8977-59FFAA51BC91Q41638338-FD72832F-387B-4382-816C-C642E966EBABQ48301410-BC8ED63A-ED1B-4DA1-AD9D-A5021B2687D6Q53627676-6725AA80-CF27-4C4C-80F7-9B5202997935
P2860
An open label clinical trial of complement inhibition in multifocal motor neuropathy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
An open label clinical trial of complement inhibition in multifocal motor neuropathy.
@en
An open label clinical trial of complement inhibition in multifocal motor neuropathy.
@nl
type
label
An open label clinical trial of complement inhibition in multifocal motor neuropathy.
@en
An open label clinical trial of complement inhibition in multifocal motor neuropathy.
@nl
prefLabel
An open label clinical trial of complement inhibition in multifocal motor neuropathy.
@en
An open label clinical trial of complement inhibition in multifocal motor neuropathy.
@nl
P2093
P2860
P1476
An open label clinical trial of complement inhibition in multifocal motor neuropathy
@en
P2093
Amanda M Fitzpatrick
Cameron A Mann
Hugh J Willison
James R Overell
Katie Brennan
P2860
P356
10.1111/J.1529-8027.2011.00328.X
P50
P577
2011-06-01T00:00:00Z